DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,647 shares of the medical device company’s stock after purchasing an additional 684 shares during the quarter. Motley Fool Asset Management LLC’s holdings in DexCom were worth $1,321,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of DXCM. Valley National Advisers Inc. increased its position in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. MV Capital Management Inc. raised its position in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the period. Washington Trust Advisors Inc. raised its position in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 193 shares during the period. Turtle Creek Wealth Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth about $57,000. Finally, NBC Securities Inc. purchased a new stake in shares of DexCom in the third quarter worth about $47,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DXCM shares. Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Canaccord Genuity Group upped their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday. Citigroup lifted their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. UBS Group boosted their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $141.67.

DexCom Stock Performance

DXCM traded down $13.67 during trading hours on Friday, hitting $124.34. 8,576,828 shares of the stock were exchanged, compared to its average volume of 3,047,021. The stock has a market cap of $49.24 billion, a price-to-earnings ratio of 97.41, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. The stock has a 50-day simple moving average of $130.98 and a 200-day simple moving average of $118.02. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. Analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock valued at $25,530,859 over the last quarter. Insiders own 0.41% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.